In vivo activity of gemcitabine-loaded PEGylated small unilamellar liposomes against pancreatic cancer

Donato Cosco, Alessandra Bulotta, Monica Ventura, Christian Celia, Teresa Calimeri, Gino Perri, Donatella Paolino, Nicola Costa, Paola Neri, Pierosandro Tagliaferri, Pierfrancesco Tassone, Massimo Fresta

Research output: Contribution to journalArticle

Abstract

Gemcitabine (GEM) is presently the standard option for the treatment of advanced pancreatic cancer (PC). We investigated the in vitro and in vivo antitumor potential of GEM-loaded PEGylated liposomes (L-GEM) as a novel agent for the treatment of PC. In vitro analysis of antitumor activity against human PC cell lines, BXPC-3 and PSN-1, showed a significant time- and dose-dependent reduction of cell viability following exposure to L-GEM as compared to free GEM [at 72 h, IC50: 0.009 vs. 0.027 μM (P = 0.003) for BXPC-3 and 0.003 vs. 0.009 μM (P <0.001) for PSN1, respectively]. Confocal laser scanning microscopy demonstrated an effective liposome/cell interaction and internalization process following 3-h cell exposure to L-GEM. The in vivo antitumor activity of L-GEM was investigated in a cohort of SCID mice bearing BxPC-3 or PSN-1 xenografts. Animals were i.p. treated with L-GEM (5 mg/kg), or a threefold increased dose of free GEM (15 mg/kg), or empty liposomes or vehicle, twice a week for 35 days. A significant higher inhibition of tumor growth in mice treated with L-GEM versus free GEM (P = 0.006 and P = 0.004 for BXPC-3 and PSN-1, respectively) or control groups (P = 0.0001), translated in a survival advantage of L-GEM treated animals versus other groups. Pharmacokinetic studies showed enhancement of systemic bioavailability of L-GEM (t1/2 = 8 h) versus to GEM (t1/2 = 1.5 h). Our findings demonstrate that L-GEM is an effective agent against PC and exerts higher antitumor activity as compared to free GEM with no appreciable increase in toxicity. These results provide the pre-clinical rational for L-GEM clinical development for the treatment of PC patients.

Original languageEnglish
Pages (from-to)1009-1020
Number of pages12
JournalCancer Chemotherapy and Pharmacology
Volume64
Issue number5
DOIs
Publication statusPublished - Oct 2009

Keywords

  • BXPC-3
  • Gemcitabine
  • Liposomes
  • Mouse models
  • Pancreatic cancer
  • PSN-1

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pharmacology
  • Pharmacology (medical)
  • Toxicology

Fingerprint Dive into the research topics of 'In vivo activity of gemcitabine-loaded PEGylated small unilamellar liposomes against pancreatic cancer'. Together they form a unique fingerprint.

  • Cite this

    Cosco, D., Bulotta, A., Ventura, M., Celia, C., Calimeri, T., Perri, G., Paolino, D., Costa, N., Neri, P., Tagliaferri, P., Tassone, P., & Fresta, M. (2009). In vivo activity of gemcitabine-loaded PEGylated small unilamellar liposomes against pancreatic cancer. Cancer Chemotherapy and Pharmacology, 64(5), 1009-1020. https://doi.org/10.1007/s00280-009-0957-1